Results 221 to 230 of about 132,795 (279)
Incidence and Predictors of Severe Adverse Drug Reactions among Patients on Antiretroviral Drugs in Harari Regional State, Eastern Ethiopia. [PDF]
Can J Infect Dis Med MicrobiolAnbessa O +3 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
The Journal of Clinical Pharmacology, 2007
The first antiretroviral drug to be licensed, zidovudine, became available in 1987. Until December 1995, the antiretroviral drugs available and approved for clinical use in the United States consisted of only 5 individual drugs belonging to a single class of antiretroviral agents, nucleoside analog reverse transcriptase inhibitors. Since then, numerous
David, Warnke +2 more
openaire +2 more sources
The first antiretroviral drug to be licensed, zidovudine, became available in 1987. Until December 1995, the antiretroviral drugs available and approved for clinical use in the United States consisted of only 5 individual drugs belonging to a single class of antiretroviral agents, nucleoside analog reverse transcriptase inhibitors. Since then, numerous
David, Warnke +2 more
openaire +2 more sources
Antiretroviral drug interactions
International Journal of Antimicrobial Agents, 1995It has recently been estimated that persons with the acquired immunodeficiency syndrome (AIDS) receive on average 5.6 prescription medications throughout their disease course, and this number may be as high as 9 [1,2]. With the development and testing of new antiretroviral agents and drugs for opportunistic infections associated with human ...
E P, Acosta, C V, Fletcher
openaire +2 more sources
Hypersensitivity to antiretroviral drugs [PDF]
European Annals of Allergy and Clinical Immunology, 2018 Background. Antiretroviral therapy (ART) may be responsible for hypersensitivity reactions varying in severity, clinical manifestations and frequency. Case report. We report the case of a 47-year-old woman with HIV infection who developed a delayed mucocutaneous reaction after treatment with ART.
M J, Sousa +5 more
openaire +2 more sources
Investigational Antiretroviral Drugs
Recent Patents on Anti-Infective Drug Discovery, 2008HIV disease is a chronic infection that requires lifelong treatment with the aim of suppressing the circulating viral load in order to improve the host immune status. The development of safe and effective antiretroviral agents with unique resistance profiles or novel mechanisms of action are an important goal for the long-term management of HIV ...
Sourav, Sen +4 more
openaire +2 more sources
Expert Opinion on Pharmacotherapy, 2013
The potency, tolerability and convenience of antiretroviral agents have all significantly improved over the past years, making lifelong HIV therapy easier. However, several specific needs are still unmet, including low daily pill burden, friendly metabolic profile, lack of (or few) drug interactions and high resistance barrier.Updated summary of ...
José Vicente, Fernández-Montero +2 more
openaire +2 more sources
The potency, tolerability and convenience of antiretroviral agents have all significantly improved over the past years, making lifelong HIV therapy easier. However, several specific needs are still unmet, including low daily pill burden, friendly metabolic profile, lack of (or few) drug interactions and high resistance barrier.Updated summary of ...
José Vicente, Fernández-Montero +2 more
openaire +2 more sources
Current HIV/AIDS Reports, 2006
Despite the availability of 21 antiretroviral drugs approved for the treatment of HIV infection, current combination regimens remain hampered by issues of toxicity, convenience, cost, incomplete viral suppression, and drug resistance. Expansion of the currently available therapeutic options through the reformulation of available agents, discovery of ...
Kimberly, Hanson, Charles, Hicks
openaire +2 more sources
Despite the availability of 21 antiretroviral drugs approved for the treatment of HIV infection, current combination regimens remain hampered by issues of toxicity, convenience, cost, incomplete viral suppression, and drug resistance. Expansion of the currently available therapeutic options through the reformulation of available agents, discovery of ...
Kimberly, Hanson, Charles, Hicks
openaire +2 more sources
Current Opinion in Pharmacology, 2010
In October 2010, it will be exactly 25 years ago that the first antiretroviral drug, AZT (zidovudine, 3'-azido-2',3'-dideoxythymidine), was described. It was the first of 25 antiretroviral drugs that in the past 25 years have been formally licensed for clinical use. These antiretroviral drugs fall into seven categories [nucleoside reverse transcriptase
openaire +2 more sources
In October 2010, it will be exactly 25 years ago that the first antiretroviral drug, AZT (zidovudine, 3'-azido-2',3'-dideoxythymidine), was described. It was the first of 25 antiretroviral drugs that in the past 25 years have been formally licensed for clinical use. These antiretroviral drugs fall into seven categories [nucleoside reverse transcriptase
openaire +2 more sources
Hepatotoxicity of Antiretroviral Drugs
Current Pharmaceutical Design, 2005The use of highly active antiretroviral therapy (HAART) has significantly slowed the HIV disease progression. However, adverse effects are now a limiting cause of HAART benefit in a substantial proportion of patients. Particularly hepatotoxicity which is a common complication occurring during every HAART regimen. All antiretroviral (ARV) drugs classes,
N, Abrescia +5 more
openaire +2 more sources